Rosiglitazone Therapy Improves Insulin Resistance Parameters in Overweight and Obese Diabetic Patients Intolerant To Metformin

Archives of Medical Research

Volumn 39, Issue 4, 2008, Pages 412-419

  Derosa, Giuseppe ^a   Salvadeo, Sibilla A T ^a   D'Angelo, Angela ^a   Fogari, Elena ^a   Ragonesi, Pietro D ^b   Ciccarelli, Leonardina ^c   Piccinni, Mario N ^d   Ferrari, Ilaria ^a   Gravina, Alessia ^a   Maffioli, Pamela ^a   Cicero, Arrigo F ^e  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c RSA Don Leone Porta   (Italy)

^d Fondazione Ospedale Della Caritá   (Italy)

^e Clinical Medicine and Applied Biotechnology Department   (Italy)

Author keywords

Adiponectin; Metformin; Plasma leptin; Resistin; Rosiglitazone; Tumor necrosis factor

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; METFORMIN; PLACEBO; RESISTIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOATING; BLOOD LEVEL; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION; DIABETIC PATIENT; DIARRHEA; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOOSE FECES; MAJOR CLINICAL STUDY; MALAISE; MALE; METEORISM; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SIDE EFFECT; SINGLE BLIND PROCEDURE; VOMITING;

ADIPONECTIN; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ITALY; LEPTIN; MALE; METFORMIN; MIDDLE AGED; OBESITY; OVERWEIGHT; RESISTIN; SINGLE-BLIND METHOD; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41149155763     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2007.12.009     Document Type: Article

References (41)

1. Kirpichnikov D., McFarlane S.I., and Sowers J.R. Metformin: an update. Ann Intern Med 137 (2002) 25-33
2. Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001) 1167-1174
3. Wagstaff A.J., and Goa K.L. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62 (2002) 1805-1837
4. Khan S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
5. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
6. Ahima R.S., and Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11 (2000) 327-332
7. Jung H.S., Youn B.-S., Ym C., Yu K.Y., Park H.J., Skin S.Y., et al. KHK. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 54 (2005) 314-320
8. Flier J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116 (2004) 337-350
9. Jackson M.B., and Ahima R.S. Neuroendocrine and metabolic effects of adipocyte derived hormones. Clin Sci 110 (2006) 143-152
10. McTernan C.L., McTernan P.G., Harte A.L., Levick P.L., Barnett A.H., and Kumar S. Resistin, central obesity and type 2 diabetes. Lancet 359 (2002) 46-47
11. Lee J.H., Chan J.L., Yiannakouris N., Kontogianni M., Estrada E., Seip R., et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88 (2003) 4848-4856
12. Kusminski C.M., McTernan P.G., and Kuman S. Role of resistin in obesity, insulin resistance and type 2 diabetes. Clin Sci 109 (2005) 243-256
13. Pajvani U.B., and Scherer P.E. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 3 (2003) 207-213
14. Berg A.H., Combs T.P., and Scherer P.E. ARCP 30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13 (2002) 84-89
15. Spranger J., Kroke A., Mohlig M., Bergmann M.M., Ristow M., Boeing H., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 361 (2003) 226-228
16. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., and Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95 (1995) 2409-2415
17. Uysal K.T., Wiesbrock S.M., and Hotamisligil G.S. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology 139 (1998) 4832-4838
18. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 30 (2007) S4-S41
19. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus: a position statement of American Diabetes Association. Diabetes Care 30 (2007) S48-S65
20. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
21. Bunn H.F., Gabbay H.K., and Gallop P.M. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 200 (1978) 21-27
22. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diab Med 16 (1999) 716-730
23. Heding L.G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8 (1972) 260-266
24. rd ed. (1988), Academic Press, San Diego
25. Misra A., and Garg A. Leptin: its receptor and obesity. J Invest Med 44 (1996) 540-548
26. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 7 (2001) 941-946
27. Yannakoulia M., Yiannakouris N., Bluher S., Matalas A.L., Klimis-Zacas D., and Mantzoros C.S. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metabol 88 (2003) 1730-1736
28. nd ed. (1971), McGraw-Hill, New York
29. Home P.D., Jones N.P., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 24 (2007) 626-634
30. Derosa G., D'Angelo A., Ragonesi P.D., Ciccarelli L., Piccinni M.N., Salvadeo S., et al. Effects of rosiglitazone and pioglitazone combined with metformin on prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Res 34 (2006) 545-555
31. Derosa G., Gaddi A.V., Piccinni M.N., Salvadeo S., Ciccarelli L., Fogari E., et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double blind, clinical trial. Diabetes Obes Metab 8 (2006) 197-205
32. Ahima R.S., Saper C.B., Fljer J.S., and Elmquist J. Leptin regulation and neuroendocrine system. Front Neuroendocrinol 21 (2000) 263-307
33. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPAR-γ ligands increase expression and plasma concentrations of adiponectin, an adipose derived protein. Diabetes 50 (2001) 2094-2099
34. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2001) 762-769
35. Ghanim H., Dhindsa S., Aljada A., Chaudhuri A., Viswanathan P., and Dandona P. A low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metabol 91 (2007) 3553-3558
36. Huypens P., Quartirer R.E., Pipeleers D., and Van de Casteele M. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. Eur J Pharmacol 518 (2005) 90-95
37. Reilly M.P., Lehrke M., Wolfe M., Rohatgi A., Lazar M.A., and Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 (2005) 932-939
38. McTernan P.G., Fisher F.M., Valsamakis G., Chetty R., Harte A., McTernan C.L., et al. Resistin in type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metabol 88 (2003) 6098-6106
39. Derosa G., Cicero A.F., Gaddi A.V., Ciccarelli L., Piccinni M.N., Salvadeo S., et al. Long-term effects of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affect by metabolic syndrome: a randomized, double-blind clinical trial. J Int Med Res 33 (2005) 284-294
40. Derosa G., D'Angelo A., Ragonesi P.D., Ciccarelli L., Piccinni M.N., Pricolo F., et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma levels in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 31 (2006) 375-383
41. Zandi E., Rothwarf D.M., Delhase M., and Hayakawa K.M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 91 (1997) 243-252